| IJCEP Copyright © 2007-All rights reserved. |
Int J Clin Exp Pathol 2(5),508-518;2009
Review Article
Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: A Distinct
Clinicopathological Entity
Shiyong Li
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
Received 28 February 2009; Accepted and available online 13 March 2009
Abstract: Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) represents a distinct subtype of mature B-cell neoplasms
in the most recent WHO classification of hematolymphoid neoplasms. It has a characteristic immunoblastic/plasmablastic morphology, a
distinct immunophenotypic profile and recurrent cytogenetic/molecular genetic abnormalities, and has been reported in both the adult and
pediatric populations. With the advent of new ALK inhibitors for possible targeted therapy clinical trials, it is important to recognize this new
entity, particularly in the pediatric population because the prognosis is worse than the more common ALK+ anaplastic large cell lymphoma.
Though rare, awareness of its existence will avoid potential misdiagnosis and facilitate appropriate management. (IJCEP902007).
Key Words: Anaplastic lymphoma kinase, ALK, diffuse large B-cell lymphoma, t(2;17), CLTC/ALK
Full text PDF
Address all correspondence to: Shiyong Li, M.D., Ph.D., Department of Pathology and Laboratory Medicine, Emory University School of
Medicine, Atlanta, GA 30322. Tel: 404-712-4140; Fax: 404-712-0819; Email: sli2@emory.edu.
Review Article
Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: A Distinct
Clinicopathological Entity
Shiyong Li
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
Received 28 February 2009; Accepted and available online 13 March 2009
Abstract: Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) represents a distinct subtype of mature B-cell neoplasms
in the most recent WHO classification of hematolymphoid neoplasms. It has a characteristic immunoblastic/plasmablastic morphology, a
distinct immunophenotypic profile and recurrent cytogenetic/molecular genetic abnormalities, and has been reported in both the adult and
pediatric populations. With the advent of new ALK inhibitors for possible targeted therapy clinical trials, it is important to recognize this new
entity, particularly in the pediatric population because the prognosis is worse than the more common ALK+ anaplastic large cell lymphoma.
Though rare, awareness of its existence will avoid potential misdiagnosis and facilitate appropriate management. (IJCEP902007).
Key Words: Anaplastic lymphoma kinase, ALK, diffuse large B-cell lymphoma, t(2;17), CLTC/ALK
Full text PDF
Address all correspondence to: Shiyong Li, M.D., Ph.D., Department of Pathology and Laboratory Medicine, Emory University School of
Medicine, Atlanta, GA 30322. Tel: 404-712-4140; Fax: 404-712-0819; Email: sli2@emory.edu.
 | |  | |  | |  | |  | |  |
